Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Cochrane Injuries Group Albumin Reviewers Cochrane Injuries Group,
Department of Epidemiology and Public Health, Institute of Child
Health, London WC1N 1EH
Ian.Roberts{at}ich.ucl.ac.uk
Objective: To quantify effect on mortality of
administering human albumin or plasma protein fraction during
management of critically ill patients.
Design: Systematic review of randomised controlled
trials comparing administration of albumin or plasma protein fraction with no administration or with administration of crystalloid solution in critically ill patients with hypovolaemia, burns, or
hypoalbuminaemia.
Subjects: 30 randomised controlled trials including
1419 randomised patients.
Main outcome measure: Mortality from all causes at
end of follow up for each trial.
Results: For each patient category the risk of death
in the albumin treated group was higher than in the comparison group.
For hypovolaemia the relative risk of death after albumin administration was 1.46 (95% confidence interval 0.97 to 2.22), for
burns the relative risk was 2.40 (1.11 to 5.19), and for
hypoalbuminaemia it was 1.69 (1.07 to 2.67). Pooled relative risk of
death with albumin administration was 1.68 (1.26 to 2.23). Pooled
difference in the risk of death with albumin was 6% (95% confidence
interval 3% to 9%) with a fixed effects model. These data suggest
that for every 17 critically ill patients treated with albumin there is
one additional death.
Conclusions: There is no evidence that albumin
administration reduces mortality in critically ill patients with
hypovolaemia, burns, or hypoalbuminaemia and a strong suggestion that
it may increase mortality. These data suggest that use of human albumin in critically ill patients should be urgently reviewed and that it
should not be used outside the context of rigorously conducted, randomised controlled trials.
Key messages
© BMJ 1998
Read all Rapid Responses